CompletedPhase 1NCT00352495
Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Studying Neurofibromatosis type 1
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Regina Jakacki, MDUniversity of Pittsburgh
- Intervention
- carboplatin(drug)
- Enrollment
- 26 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2006 – 2012
Study locations (21)
- Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States
- Children's Hospital of Orange County, Orange, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
- C.S. Mott Children's Hospital at University of Michigan Medical Center, Ann Arbor, Michigan, United States
- Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St Louis, Missouri, United States
- Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
- SUNY Upstate Medical University Hospital, Syracuse, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Oregon Health and Science University Cancer Institute, Portland, Oregon, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- +6 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00352495 on ClinicalTrials.govOther trials for Neurofibromatosis type 1
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06507748A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07102394Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1Johns Hopkins University
- RECRUITINGNANCT07221331Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)AstraZeneca
- RECRUITINGNANCT07088991Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsiaAstraZeneca
- RECRUITINGPHASE1NCT06961565PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform NeurofibromasPasithea Therapeutics Corp.
- RECRUITINGNANCT06880991Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative StudyNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06541847A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1Healx Limited
- RECRUITINGNANCT06222203Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)National Cancer Institute (NCI)